Fundraising Fox

Epiodyne

San Francisco, US · Founded 2016 · Delaware corporation · 3 known investors

epiodyne.com ↗

Epiodyne develops small-molecule opioids designed to optimize therapeutic outcomes, with initial focus on safer pain relief and improved opioid use disorder treatment with reduced addiction and respiratory depression risk. The company uses a platform approach to tune drug candidates across a spectrum from inhibitors to full agonists.

BiotechHealthtechMedical Devices

Founders & leadership

DC
Douglas Crawford, Ph.D.CEO
DGDon Gehlert, Ph.D.
Don Gehlert, Ph.D.Head of Biology
BS
Brian ShoichetDirector
DC
Douglas CrawfordExecutive Officer, Director

Investors · 3

Menlo Ventures✓ verifiedSan Francisco · $1M – $20M
Mission Bay CapitalSan Francisco
Mission BiocapitalSan Francisco · $500K

Reported raises · per SEC filings

Form D private placements
▶$8MraisedApr 2019 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alex TkachenkoExecutive Officer, Director
  • Brook ByersDirector
  • Douglas CrawfordDirector
Offering amount
$8M
Amount sold
$8M
First sale
Jul 2018
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.8MraisedNov 2017 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Brook ByersDirector
  • Douglas CrawfordDirector
  • Alex TkachenkoExecutive Officer, Director
Offering amount
$10.1M
Amount sold
$5.8M
First sale
Oct 2017
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$500KraisedJun 2016 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Douglas CrawfordExecutive Officer, Director
  • Brian ShoichetDirector
Offering amount
$500K
Amount sold
$500K
First sale
Jun 2016
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news